OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacological Reviews is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-09-01 to 2024-09-01.)

Article	Citations
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies	466
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels	311
Is Oxytocin “Nature’s Medicine”?	229
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges	224
Rescuing the Last-Line Polymyxins: Achievements and Challenges	205
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development	185
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function	162
Subcellular Organization of the cAMP Signaling Pathway	162
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials	159
Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology	128
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms	120
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics	107
Post-Translational Modifications of G Protein–Coupled Receptors Control Cellular Signaling Dynamics in Space and Time	101
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950	97
Sex- and Gender-Based Pharmacological Response to Drugs	96
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update	85
Dopamine, Immunity, and Disease	82
Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You?	82
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review	76
Mutations in G Protein–Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches	74
Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species	73
Aldo-Keto Reductases and Cancer Drug Resistance	70
Unlocking G-Quadruplexes as Antiviral Targets	67
Animal Models of Drug Relapse and Craving after Voluntary Abstinence: A Review	65
E1 Enzymes as Therapeutic Targets in Cancer	62

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications	60
Inhaled Medicines: Past, Present, and Future	55
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain	53
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning	49
Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease	47
Neurobiological Mechanisms of Nicotine Reward and Aversion	47
Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors	46
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications	44
Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction	43
The Angiotensin AT₂Receptor: From a Binding Site to a Novel Therapeutic Target	43
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development	42
The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors	42
Sex/Gender Differences in the Time-Course for the Development of Substance Use Disorder: A Focus on the Telescoping Effect	42
Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain	42
Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders	39
Gαs–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling	39
International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors	39
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein	39